Multinational Suitors Queue Up As India's Paras Pharma Valuation Shoots Above $1 Billion

MUMBAI - As prospective multinational suitors queue up to clinch a majority equity stake in Paras Pharma - a fast-growing Indian OTC and cosmetic company - leading investment bankers have questioned whether the asking price is "unreasonable and exaggerated.